Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- BindRen Approved in Europe for Hyperphosphatemia: MTPC
January 31, 2013
- Chugai Files NDA for Antibody-Drug Conjugate T-DM1 for HER2-Positive Breast Cancer
January 31, 2013
- Higher Dose of Toviaz Further Reduces Urge Urinary Incontinence in Patients with OAB: Pfizer
January 31, 2013
- TS-1 Superior to Gemcitabine in Extending OS of Resected Pancreatic Cancer Patients in PIII Study: Taiho
January 30, 2013
- No New Safety Concerns Found in All-Case PMS of Vectibix: Takeda
January 30, 2013
- “Hybrid” Bioventures Might Help Japanese Pharmas Compete in the Global Market: Prof. Kneller
January 30, 2013
- Number of MR-Qualified MSs Reaches 840 with 376 Newly Passing MR Exam: Medipal Group
January 30, 2013
- Nesina Approved in US: Takeda
January 29, 2013
- Medipal Group Introduces Special Mini Cooler for New Orphan Drug
January 29, 2013
- Kyowa Kirin to Apply for KRN125 in 2013
January 28, 2013
- Ono, DSP Cancel Development of Limaprost for CTS
January 28, 2013
- Novartis AG: Annual Sales Down, Profits Up, Gilenya Reaches Blockbuster Status
January 28, 2013
- Market for Novel Oral Anticoagulants to Heat Up as More Companies Compete for Low-risk Patients
January 28, 2013
- Otsuka to Hire 55 Grads of 6-Year Pharmaceutical Universities as MRs in FY2013: Jiho Poll
January 25, 2013
- Novartis, Sanofi Dissolve Partnership on Equa Copromotion
January 25, 2013
- AIMIX Ranks No.1, Lotriga Soars in GP Market: Rep Track Survey
January 25, 2013
- JSMI Chief Yoshino Voices Disagreement with JMA on Epadel OTCs
January 25, 2013
- Transparency GL: Drug Makers Might Disclose Individual Payments Only Upon Request
January 24, 2013
- Takeda Establishes Trading Company in China to Serve as Base for Import of Finished Products
January 24, 2013
- Bayer, Santen Aim to Lead Market with Simpler Eylea Administration
January 24, 2013
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…